Speciality Medicines Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Speciality Medicines Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹124
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,24,000
Issue Size
₹29.14 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
49%
QIB Quota
2%
NII Quota
49%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Speciality Medicines Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
59.67%
Promoter Holding (Post-Issue)
43.26%
Issue Type
Book Building - SME
ISIN
INE0R0M01014
About the Company
The Company is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases.We offer a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Our products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. We operate through two integrated business models: (a) Manufacturing, through contract manufacturing basis, of approved finished formulations and distribution internationally and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers.
Industry Overview
India is the largest provider of generic drugs globally, accounting for approximately 20% of the global supply by volume and contributes over 60% of the global vaccine demand. As of 2024, India is home to over 3,000 pharmaceutical companies and more than 10,000 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. This has positioned the country as a critical part of the global pharmaceutical supply chain, especially for regulated markets such as the United States, European Union, and Japan.
Company History
The Company was originally incorporated as "Speciality Medicines Private Limited" as a Private Limited Company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre. Later on, pursuant to a special resolution passed by its Shareholders in the Extra-Ordinary General Meeting held on April 04, 2024, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed from "Speciality Medicines Private Limited" to "Speciality Medicines Limited" and a fresh certificate of incorporation dated June 25, 2024 was issued to our Company by the Registrar of Companies, Central Registration Centre. The Corporate Identification Number of our Company is U85300GJ2021PLC120022.
Products & Services
- The Company is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products.
Growth Strategy
- Identify Target Markets.
- Initial Lead Interaction (Exhibition, Seminar, Conference).
- Mobilize Business Development Team.
- Leveraging Market Skills and Relationships.
- Key Customer Relationship Building.
- Increasing Operational Efficiency.
- Market Share Expansion Initiatives.
- Investing in Formulation and Development Centre
- Increase Global Presence
- Participation in Exhibitions and Industry Forums
- Increasing Operational Efficiency
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public issue of up to 23,50,000 equity shares of face value of Rs. 10/- each of Speciality Medicines Limited ("SML" or the "Company" or the "Issuer") for cash at a price of Rs. 124 per equity share including a share premium of Rs. 114 per equity share (the "Issue Price") aggregating to Rs. 29.14 Crores ("the Issue"), of which up to 1,50,000 equity shares of face value of Rs.10/- each for cash at a price of Rs. 124 per equity share including a share premium of Rs. 114 per equity share aggregating to Rs. 1.86 Crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. Net issue of 22,00,000 to be updated equity shares of face value of Rs. 10/- each at a price of Rs. 124 per equity share including a share premium of Rs. 114 per equity share aggregating to Rs. 27.28 Crores is herein after referred to as the "Net Issue". The issue and the net issue will constitute 26.75% and 25.04%, respectively, of the post issue paid up equity share capital of the company. The face value of the equity shares is Rs. 10/- each. Price Band: Rs. 124 per equity share of face value of Rs. 10 each. The floor price is 12.40 times of the face value. Bids can be made for a minimum of 2000 equity shares and in multiples of 1000 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- A Supplier of Specialty pharmaceuticals.
- Experienced Promoters and Management Team.
- Diversified Business Operations and Revenue Base.
- Scalable Business Model.
- Quality Assurance.
- The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
- The company is subject to strict technical specifications, quality requirements by its customers. The company failures to comply with the quality standards and technical specifications prescribed by such customers may lead to loss of business from such customers and could negatively impact its business, results of warranty claims.
- The pharmaceutical market is subject to extensive regulation and failures to comply with the existing and future regulatory requirements in any pharmaceutical market could expose it to litigation or other liabilities, which could adversely affect its reputation, business, financial condition and results of operations.
- The company limited operating history may make it challenging for investors to assess its future growth prospects and overall business performance since the company was incorporated on February 05, 2021, which makes it a relatively new entity with a short track record of business and financial activities.
- The company business is working capital intensive. If its unable to borrow to meet the company working capital requirements, it may materially and adversely affect its business and results of operations.